DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Alliance Natural Active Ingredients for Cosmetics
Zwingenberg, Germany, 2 August 2017 To this end, BRAIN contributed its specific competencies in the field of identifying natural active substances from its proprietary BioArchive and additionally provided its unique expertise in the receptor technologies sector. Receptor technologies developed by BRAIN serve at laboratory level to predict substance effects on human sense organs. Such a laboratory procedure was successfully established during the research partnership with BASF. BASF transferred the jointly generated research results to the development and marketing of innovative product candidates. These development efforts have since led to one product's being successfully launched in the market. Dr Michael Krohn, member of BRAIN's Board of Management and Head of the BioActives & Performance Biologicals Unit states: "We are delighted about the successful conclusion of the research partnership with BASF - particularly about the fact that a first product based on our receptor technologies was already launched in the market. At BRAIN, we use these technologies not only for sustainable cosmetics applications, but also for healthier food developments. For instance, this segment focuses on natural sugar substitutes, sweetness enhancers or taste modulators. Our high-tech portfolio permits us to deliver reliable results in any joint R&D endeavour, and we have more than 100 successfully concluded cooperation projects under our belt." Sales-wise, BRAIN's research cooperation activities are reflected in its BioScience segment, which focuses on exclusive R&D collaborative partnerships with industrial companies. The cooperation partners have agreed to keep contract details about the successfully concluded research cooperation project confidential. About BRAIN B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. www.brain-biotech.de/en.
02.08.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | B.R.A.I.N. Biotechnology Research And Information Network AG |
Darmstädter Straße 34-36 | |
64673 Zwingenberg | |
Germany | |
Phone: | +49 (0) 62 51 / 9331-0 |
Fax: | +49 (0) 62 51 / 9331-11 |
E-mail: | ir@brain-biotech.de |
Internet: | www.brain-biotech.de |
ISIN: | DE0005203947 |
WKN: | 520394 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |